Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07107607 · ClinicalTrials.gov registry record
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
A clinical trial of Cancer and Cancer (With or Without Metastasis), sponsored by HealthPartners Institute.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07107607: Recruiting study of Cancer and Cancer (With or Without Metastasis), sponsored by HealthPartners Institute.
NCT07107607 is a study of Cancer and Cancer (With or Without Metastasis) that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07107607, a study of Cancer and Cancer (With or Without Metastasis), is actively recruiting participants, sponsored by HealthPartners Institute.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Primary Outcome
Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.
Conditions Studied
Study Locations (1)
Minnesota
- HealthPartners Institute Cancer Research Center - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2027-01 |
What NCT07107607 shows while recruiting
NCT07107607 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07107607 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07107607 about?
NCT07107607 is a clinical study titled "Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)". The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
What is the current status of trial NCT07107607?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-03-19. Estimated completion is 2027-01.
What conditions does trial NCT07107607 study?
This clinical trial studies the following conditions: Cancer, Cancer (With or Without Metastasis).
Who is sponsoring clinical trial NCT07107607?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07107607 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07107607's enrollment target sits among peer trials
50 422nd of 615 higher than 179 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI